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ABSTRACT
Blood vessel maturation is characterized by the recruitment and attachment of vascular smooth
muscle cells (vSMCs) around immature blood vessels, which ultimately form the tunica media.
Improper maturation can lead to vascular birth defects ranging from minor birthmarks to lethal
brain aneurysms. Previously, our lab demonstrated that hemodynamic force plays an important
role to regulate vSMCs recruitment from neighboring low-flow to high-flow vessels followed by
the attachment of these vSMCs to the high-flow vessels. To understand the reason for the
preferred attachment of vSMCs to high-flow vessels, instead of low-flow vessels, I hypothesize
that hemodynamic force modulates the expression of extracellular matrix genes to promote the
deposition of a thick basement membrane around the immature high-flow vessels to increase its
adhesiveness to migrating vSMCs. To test this hypothesis, I utilized an extraembryonic tissue
called the yolk sac, which is a thin/transparent membrane only comprised of simple blood
vessels, and I compared gene expression differences by qPCR between yolk sac tissues under
normal blood flow with those having reduced blood flow. I found that there is a decrease in
matrix metalloproteinase-9 (MMP-9) expression in high-flow vessels as compared to low-flow
vessels. My data support our hypothesis as lowering MMP9 should promote deposition of a
thicker basement membrane, thus enhancing the attachment of vSMCs to high-flow vessels.
KEYWORDS: vascular smooth muscle cells, vessel maturation, hemodynamic force,
extracellular matrix genes, basement membrane.
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INTRODUCTION

The cardiovascular system is the first functional organ system that starts working at the
beginning of the fourth week of embryonic development in humans (Mathew, Bordoni, 2021).
In mammals, the cardiovascular (CV) system is composed of the heart and blood vessels. Its
major role is to enable gas exchange, supply nutrients, and remove waste products, but it also
plays a role in endocrine signaling and serves as a conduit for the movement of immunological
cells throughout the body (Udan, Culver, & Dickinson, 2013). At the center of the CV system is
the heart. The heart is comprised of left and right atria and left and right ventricles. Through
coordinated contractions, blood is efficiently pumped to the lungs or to the body via the
vasculature. The right side of the heart receives deoxygenated blood from the body and transfers
it to the lungs to be oxygenated. The left side of the heart receives the oxygenated blood from the
lungs and transmits it to the rest of the body through the vasculature. The vasculature is a
complex system comprised of a hierarchy of different vessel subtypes (from arteries to arterioles,
capillaries, venules, and veins). Arterial walls are thicker and more elastic than other vessels to
withstand the high blood pressure, whereas veins are less elastic and less muscular due to the
presence of reduced blood pressure. Capillaries, which have lower blood flow and are much
smaller, facilitate the diffusion of gases and nutrients. Collectively, the heart and vasculature are
highly organized structures that are required for embryonic/fetal survival.

Role of the Cardiovascular System During Development
The CV system forms during embryonic development. When a mammalian embryo
embeds into the uterus, it is still devoid of a CV system, but eventually, it develops one to meet
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increasing metabolic demands of the embryo. Through several cellular and molecular
mechanisms, some known and some unknown, the CV arises. However, there are some
situations where the CV system does not form, or it does not form properly, and this can be
disadvantageous to human health.

Relevance to Human Health
The way in which defective CV development can impact the health of people is through
the formation of congenital heart and vascular defects. For example, there are a wide variety of
congenital heart defects (CHDs) that affect the size of the heart or thickness of the heart tissue.
They can also affect the separation of the chambers of the heart or the fusion of the vessels that
are directly connected to the heart (Suluba, Shuwei, Xia, & Mwanga, 2020). Those defects can
impair normal blood flow and can affect further heart development. Children born with CHDs
may develop some complications like developmental delay, repeated respiratory infection,
pulmonary hypertension, and heart failure while other children may not experience
cardiovascular issues until much later in adulthood.
Another type of defect in the development of the CV system is congenital vascular
anomalies (CVAs). CVAs can affect different vascular structures like arteries, veins, lymphatic
vessels, and capillaries separately, or sometimes involve two or more vascular structures that are
known as mixed lesions (Eerola, Boon, Mulliken 2003). Though less prevalent, there are a wide
variety of these anomalies. For example, arterial-venous fistulas, hemangiomas, and congenital
aneurysms. Clinical presentations depend on the type of malformation, location, size, and
relationship with other structures and can be named according to the affected structure.
Arteriovenous (AV) fistulas are an abnormal connection between an artery and a vein without an

2

intervening capillary bed that can lead to venous hypertension, arterial insufficiency, high
cardiac output failure, and hemorrhage (Jayroe, 2020). Children can be born with this condition
in different locations of the body including pulmonary, hepatic, aortocaval, coronary, and
carotid-cavernous vessels (Reynolds, Lanzino, & Zipfel, 2017). Despite the frequent occurrence
of these conditions, the etiology of AV fistulas is not well understood.
A congenital aneurysm is a rare case that can occur where infants are born with weak
vessels having thin layers of tissues. Weak or thin-walled vessels are prone to hemorrhaging, and
in some cases, they only cause birthmarks, but in other cases, it can involve larger vessels that
are prone to rupture later in life. In cerebral aneurysms, most of the aneurysms are located along
the bifurcation of the Circle of Wills which can cause subarachnoid hemorrhaging (SAH) after
rupture. A rupturing aneurysm is one of the major causes of atraumatic SAH in children, and
approximately 65% of patients present with rupture at the time of diagnosis (Amacher & Drake,
1975). Sudden thunderclap headache, loss of consciousness, seizure, and coma are the common
presenting features of a ruptured aneurysm, and some patients may present with recurrent
bleeding episodes. The overall mortality rate of children after a ruptured aneurysm is 13% to
34% (Levy, 2021).
To understand how these vascular anomalies such as congenital aneurysms arise, we first
must learn the fundamental mechanisms governing the growth, development, and maturation of
these vessels. This will allow us to elucidate important mechanisms and molecules needed for
proper growth of the vasculature, and this information may also allow us to develop therapeutic
approaches to repair improperly developed vessels. Knowledge about vascular maturation is also
important in utilizing tissue-engineering approaches (Jain, 2003). Every year many people need
organ transplantation but one of the major impediments in organ transplantation is finding an
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appropriately matched donor. The problem in donor finding can be solved by designing artificial
organs. One of the challenges of designing artificial organs is developing a functional 3D
vasculature to regulate blood flow to the organ. Uncovering the unknown information about
cellular, molecular, and biochemical cues of blood vessel formation can help in designing a
functional vasculature.

Current Views on Cardiovascular Development
The early post-implantation mammalian embryo lacks a CV system because it is
supported by simple diffusion of gas and molecules from the maternal tissues. However, as the
embryo increases its size, it will need a functional circulatory system (Udan, Vadakkan, &
Dickinson, 2013). How does the cardiovascular system form?

Development of the Mouse Heart
Much of what we know about heart development has been elucidated in model organisms
such as the mouse. In the mouse, heart development begins with a subset of lateral plate
mesoderm, referred to as cardiogenic mesoderm, found on the left and right sides of the
developing embryo (Paige, Plonowska, Xu, & Wu, 2015). This cardiogenic mesoderm coalesces
into two tubes of tissues. Each tube is comprised of an inner layer (endocardium) and outer layer
(myocardium), and these tubes ultimately fuse together to form one unit referred to as the heart
tube. This heart tube will continue to develop by a process of looping, ballooning, septa growth,
and valve growth (Anderson, Webb, Brown, Lamers, & Moorman, 2022). This results in a fourchambered heart that ultimately becomes connected to the following vessels (aorta and vena
cava, and pulmonary artery and vein).

4

Development of the Mouse Vasculature
Vessel development in the mouse begins slightly earlier than the heart. It occurs initially
at several sites (the yolk sac, the embryo, and the chorion/placenta). Vessel development begins
by the process of vasculogenesis. Vasculogenesis is a de novo process where endothelial cell
precursors (angioblasts) assemble and form a new functional vessel. This process is not limited
only during embryogenesis, but it can occur at different stages from embryogenesis to adulthood.
To start vasculogenesis, the angioblasts must first be specified. Regardless of the location of
vasculogenesis, all angioblasts form from a subset of mesoderm. One of the important signaling
molecules that helps to specify angioblasts from the mesoderm is the vascular endothelial growth
factor (VEGF) (Ferrera, 2000). VEGF binds to a subset of mesoderm via its cognate receptor,
vascular endothelial growth factor receptor 2 (VEGFR2). VEGF has been shown to be important
in specifying angioblasts, and hence endothelial cells. This is based on evidence revealing that
removal of VEGF signaling impedes endothelial cell formation (Shalaby et al., 1995).
In the mouse embryo, the angioblasts that are specified by VEGF arise from a subset of
mesoderm that is actively migrating through the primitive streak. These cells ingress between the
epiblast and primitive endoderm layers through a circular cavity known as a primitive pit.
Eventually, these cells arrive at the embryo proper (where the intraembryonic vessels form), as
well as the extraembryonic region of the embryo (where the yolk sac vessels form).
The yolk sac is the first location where vasculogenesis takes place. In the yolk sac,
angioblasts are found in close proximity to hematopoietic precursor cells. Here, the angioblasts
surround the hematopoietic precursor cells and form several clusters of cells called blood islands
(Udan, Culver, et al., 2013). These blood island cells condense (allowing angioblasts to adhere to
each other) and the angioblasts between neighboring blood islands adhere with one another. This
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ultimately results in a network of interconnected tubes of angioblasts (now called endothelial
cells) that surround the hematopoietic precursor cells that are referred to as primitive blood cells
(Majesky, 2018; Patan, 2004; Risau & Flamme, 1995). Here the network is called a capillary
plexus. During this process, the tubes become lumenized and filled with plasma.
Shortly after extraembryonic vessel formation in the mouse embryo at embryonic day (E)
7.3, the dorsal aorta starts to form from the intraembryonic angioblasts as two separate vessels
that later fuses in the midline to form one single vessel (Collart et al., 2021). There are some
differences between extraembryonic and intraembryonic vessel formation. During
intraembryonic vascular formation, the new vessels do not surround hematopoietic precursor
cells, as in the yolk sac vessels. However, in a small paraaortic region, and at a slightly later
stage, some of the blood vessel endothelial cells have hemogenic potential, as they have been
shown to be hemogenic endothelium, which are cells capable of giving rise to primitive blood
cells (Garcia, Lopez, Larin, & Larina, 2015). However, a majority of early embryonic
erythropoiesis occurs almost exclusively at the yolk sac.
One of the last steps before the onset of angiogenesis in mouse embryos is the connection
of the extraembryonic/yolk sac vasculature and the intraembryonic vasculature with each other
as well as to the heart. This occurs at E8.0 and is quickly followed by the initiation of heart
contractions at E8.25. During this time, the force of plasma flow allows for the primitive blood
cells in the yolk sac vessels to enter circulation, resulting in blood moving into the heart and
through the dorsal aortae. Thus, a circulatory connection develops between extraembryonic and
intraembryonic tissues.
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Angiogenesis
Angiogenesis is the formation of vasculature from pre-existing vasculature. This process
is not only limited to developing embryos but can occur in different stages of life in response to
hypoxia, wound healing, and tumor growth. In adult life, this process needs to be regulated
tightly because both overproduction and reduced production of blood vessels can be associated
with diseased conditions. Tissue hypoxia can activate the cellular production of VEGF and
cytokines that are the key regulators to start angiogenesis. VEGF together with NOTCH
signaling can exert diverse biological effects like endothelial cell differentiation, migration,
maintaining vascular diameter, and so on. In the mouse embryo, angiogenesis starts
approximately at E8.5 from the newly formed primitive vascular plexus (Lucitti et al., 2007).
Angiogenesis may occur via four distinct mechanisms such as sprouting, fusion, intussusception,
and regression.
The predominant mechanism governing angiogenesis is a process called sprouting.
Sprouting angiogenesis is a process where specialized endothelial cells (found within functioning
vessels) grow a new vessel (called a sprout) to create a new tube that ultimately connects to
another vessel. When this is repeatedly done, it forms a new functional vascular network. To
start sprouting, endothelial cells turn into two distinct phenotypic forms known as tip cells and
stalk cells; each having special functional characteristics. Endothelial cells which are exposed to
the highest amount of VEGF through its receptor (Vegfr2) turn into tip cells. Tip cells are in the
distal end of the sprouting vessel and can migrate due to the presence of lamellipodia and
filopodia extensions. Due to VEGF signaling, tip cells upregulate expression of the notch ligand,
delta like ligand-4 (Dll4), which plays an important role in specifying stalk cells in neighboring
cells, as well as proteinases that promote sprouting into the surrounding tissue. Through Dll4
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induction of notch signaling in neighboring cells, the identity of those neighboring cells become
stalk cells (D’Alessio, Moccia, Li, 2015). These endothelial stalk cells have fewer filopodia, but
a higher proliferative capacity, allowing a new vessel to extend outward into the tissue. In
addition, stalk cells stabilize the new sprout by expressing adherens junction proteins and
creating the lumen in the new vessel. To ensure stalks cells do not become tip cells, the elevated
notch signaling within the stalk cells results in a decrease in VEGFR2 expression. This reduces
the cellular response of stalk cells to VEGF. After specification of the tip cell and the stalk cells,
vessel outgrowth occurs perpendicularly due to the release of soluble fms like tyrosine kinase
(FLT1) from the stalk cells, which causes a steepness of VEGF gradient and enhances
proliferation of stalk cell, so that the vessel grows outwardly.
Fusion is another process of angiogenesis where vessels combine. This can occur by
joining two sprouts together in a process called anastomosis or by fusing two parallel blood
vessels together. Though the exact mechanism of the latter process is not known, in the former
process, macrophages can secret VEGF-C, which promotes the conversion of two contacting tip
cells to form new stalk cells, resulting in the fusion of two sprouted blood vessels (Tamella,
Zarkada, et al., 2011).
Another mechanism to either create new vessels, or to change the branching angles of
vessels is called intussusception or splitting angiogenesis. This process is essentially the opposite
of fusion. Intussusception occurs by the formation of intraluminal vascular pillars that invaginate
into a capillary lumen. Though this form is the least common, this process has been observed in
different species and in different organs/tissues like the lung, chorioallantoic membrane, kidney,
heart, and endometrium (Udan, Culver, et al., 2013). According to morphological characteristics,
intussusception can be divided into three types such as intussusceptive microvascular growth,
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intussusceptive arborization, and intussusceptive branching remodeling. Intussusceptive
arborization can help in vascular remodeling by creating new vessels, whereas intussusceptive
branching remodeling changes the angles of blood vessel branches.
The last mechanism of angiogenesis, vascular regression, is utilized to remove
supernumerary vessels. It is the systemic pruning of unnecessary vessels to create a stable
vascular network that is important to maintain vascular homeostasis. Various factors including
reduced shear stress and decreased hypoxia can cause vascular pruning by inducing antiangiogenic signaling (Ricard & Simons, 2015).
In early development, newly formed blood vessels are mostly equivalent in diameter.
However, they eventually develop into different diameters to form a hierarchy. This occurs by
the process of vascular remodeling, which utilizes some of the processes of angiogenesis.

Developmental Vascular Remodeling
Developmental vascular remodeling is a process that leads to the correct branching and
growth (diameter increase) of vessels to form a hierarchy of large-diameter proximal vessels
(located closer to the heart) that branch into small-diameter distal vessels (located away from the
heart). This hierarchy is crucial in directing blood to tissues and to facilitate diffusion in small
capillaries while maintaining the correct dimensions that allow for the heart to physically pump
blood through the body.
Vascular remodeling takes place in the mouse between E8.5-9.5 (Armulik, Abramsson, &
Betsholtz, 2005), and any impairment of remodeling halts further development of embryos since
underdeveloped vessels will fail to provide oxygen and nutritional support to the tissues).
Besides molecular cues, it has long been known that hemodynamic force plays a very critical
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role in vascular remodeling, as disruptions in normal blood flow in mouse embryos result in a
failure for the blood vessels to properly remodel. For instance, functional mutation of myosin
light chain 7 (Myl7 / Mlc2a), which is a structural component of atrial myofibril, can disrupt the
ability of the atria of the heart to contract, only allowing the ventricles to pump blood throughout
the embryo. As a result, this reduces the hemodynamic force that the blood vessels of the embryo
are exposed to, which results in impairment in vascular remodeling at E9.5 (Lucitti et al., 2007).
To prove that impaired vascular remodeling was specifically caused by a reduction in
hemodynamic force, and not due to inadequate oxygenation of the tissue, Lucitti et al.
compromised remodeling in a different way, by experimentally removing erythroblasts from
cultured mouse embryos to produce low-hematocrit embryos (Lucitti et al., 2007). This lowers
the viscosity of the plasma, which in turn reduces the hemodynamic force that the vessels are
exposed to. Then, the researchers were able to rescue the vascular remodeling defect in the lowhematocrit embryos by injecting hetastarch into the vessels. Since hetastarch does not provide
oxygenation to the tissues but does increase plasma viscosity, the experiment demonstrated that
the hemodynamic force exerted by flow was essential for vascular remodeling.
To understand how hemodynamic force accounts for the changes in vessel diameter that
occur during remodeling, another study was performed using live confocal imaging to visualize
vessel diameter increases (Udan, Vadakkan, et al., 2013). In this study, the dynamics of vessel
remodeling were visualized by comparing the proper remodeling that occurs in normal-flow
mouse embryos (wild type) versus the abnormal remodeling that occurs in reduced-flow (Myl7-/-)
mouse embryos. Results from that study revealed that normal-flow mouse embryos exhibit a
variation of hemodynamic force throughout the vascular bed (in this case the yolk sac tissue).
Vessels that have high blood flow (high hemodynamic force) and tend to be located closer to the
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heart (proximal) then fuse with neighboring vessels to create larger-diameter vessels. Also, the
proximal vessels continue to grow larger, as endothelial cells can migrate collectively towards
the proximal vessel. This further increases diameter of the proximal vessel, while diminishing
vessel diameter at vessels located farther away from the heart and downstream (distal vessels).
Interestingly, hemodynamic force is required for these dynamic cell and tissue movements, as
reduced-flow embryos lack the ability for vessels to fuse and for the endothelial cells to migrate
towards proximal vessels. Therefore, it is obvious that hemodynamic force plays a crucial role in
vascular remodeling.

Artery/Venous Specification
Before vascular remodeling occurs, the vessels begin to display differences based on their
proximity and location to the heart. Vessels that pump blood away from the heart become
arteries, and those that move blood toward the heart become veins. There is much experimental
evidence to show that arterial and venous identities are specified before remodeling. Several
genetic mechanisms may be involved including Notch signaling and Ephrin/Eph receptor
signaling (Lawson, Scheer, Pham, Kim, & Chitnis, 2001). In the mouse yolk sac vessels,
presence of EphrinB2 determines arterial endothelial cell and EphrinB4 determines venous
endothelial cells (Fang & Hirschi, 2019). Also, Notch and their downstream effector molecules
are required for arterial specification, whereas venous specification does not require Notch
signaling. However, other evidence suggests that these identities are not necessarily irreversible,
as they have to be reinforced/maintained during vascular remodeling (Oliver & Srinivasan,
2010). For example, Le Noble et. al showed that ligation (blockage of blood flow) in the right
vitelline artery of chick embryos resulted in a downregulation of several arterial markers (le
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Noble et al., 2004) whereas, in mouse embryos, cessation of flow only results in a
downregulation of some arterial markers but not others (Jones, Yuan, Breant, Watts, &
Eichmann, 2008). The consensus within the field, from studies such as these, is that
hemodynamic force is not required for arterial/venous specification, but instead is required for
maintaining expression or arterial or venous markers/fates (Buschmann et al., 2010; Campinho,
Vilfan, & Vermot, 2020). Once specified, arteries can adopt structural differences than veins
such as a thicker layer of surrounding tissue while veins can adopt a larger diameter than arteries
and the presence of valves.

Vascular Maturation
After vessel hierarchy forms, the next step is for the vasculature to become surrounded by
extra layers of cells. In E9.0 mouse embryos, the vasculature is just a single-cell layer of
endothelial cells, but in the mature embryo, fetus, and adult, vessels can form multiple layers in a
process called vascular maturation. Vascular maturation occurs by the recruitment and
attachment of mural cells around the newly remodeled endothelial layer. Mural cells can be
either vascular smooth muscle cells (vSMCs) or pericytes. Pericytes usually cover micro vessels
like capillaries and vSMCs deposit around large diameter vessels as a tissue layer. A mature
vasculature usually contains three layers of tissues, such as the tunica intima, tunica media, and
tunica adventitia. The tunica media is the middlemost layer formed by the deposition of vSMCs
around an immature blood vessel which is crucial to maintain vascular tone and integrity. There
is also an outer layer referred to as a tunica adventitia. It is comprised of connective tissues cells
that deposit an extracellular matrix, provide elasticity, and support to the vessel, and allow the
vessels to connect to other tissues. Interestingly, the existence and number of layers vary
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depending on the vessel subtype. Arteries have a thick tunica media to withstand with large
pressure force generated by transporting oxygenated blood throughout the body. The tunica
media of the vein is thinner than arteries and capillaries (the latter being usually devoid of tunica
media).
Though vascular maturation has been studied for many years, queries regarding the
molecular mechanisms of this process remains unclear. It was long known that during
maturation, endothelial cells secret platelet-derived growth factor b (PDGFB) which is a key
regulatory molecule for vSMC recruitment and proliferation (Lindblom et al., 2003). But new
studies suggest that instead of recruitment, PDGFB acts to enhance the proliferation of vSMCs
only. It has been observed that any mutation in PDGFB reduces the total number of vSMCs, but
available vSMCs are still have the capability to recruit to the vessel (French, Creemers, &
Tallquist, 2008). So, there must be some other mechanism that regulates vSMCs recruitment.
Upon recruitment, vSMCs undergo reciprocal signaling by releasing AGPT1 (Angiopoietin1) to
activate the TEK receptor in endothelial cells, which is thought to activate the endothelial
expression of adhesion molecules to promote vessel stability. Stabilization of immature vessels
make them leak resistant. Transforming growth factor β 1(TGFβ1) is another important factor of
vessel maturation that is activated after vSMC-EC interaction. TGFβ1 promotes vascular
maturation by promoting extracellular matrix (ECM) formation and by initiating differentiation
of mesenchymal cells into vSMCs. Though these signaling molecules seem to play a role in
vessel stability and vSMC-EC attachment, it is not clear whether they play a role in controlling
the extent of vSMC coverage in different vessels of the hierarchy. Part of the mechanism for
understanding the control of this hierarchical difference in tunica media coverage was elucidated
in the Udan lab (Padget, Mohite, et al., 2019).
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The Role of Hemodynamic Force in Regulating Vascular Maturation
An interesting observation regarding the regulation of vascular maturation is the
differences in vSMC coverage throughout the vascular hierarchy. For example, proximal arteries
of the developing mouse yolk sac contain the highest vSMC coverage, whereas, extent of
coverage diminishes gradually in proximal veins and capillaries (Padget, Mohite, et al., 2019).
This difference provides the first clue that hemodynamic force may be responsible for regulating
the extent of vSMC coverage, as these different vessels of the yolk sac have a matching level of
hemodynamic force (Udan, Vadakkan, et al., 2013). Specifically, proximal arteries have the
highest hemodynamic force and greater amount of vSMCs coverage. Whereas capillaries have
the lowest vSMCs coverage and the lowest hemodynamic force. To determine whether
hemodynamic force is required for vascular maturation, Padget et al. sought to determine if
reduction of hemodynamic force (in Myl7-/- mutant embryos/yolk sacs) impairs maturation
(Padget, Mohite, et al., 2019). Indeed, reduction of hemodynamic force results in a reduction of
vSMC coverage, including in the proximal arteries of the yolk sac, as well as the dominant
intraembryonic vessel, the dorsal aortae. To determine the cellular mechanism of this diminished
vSMC coverage, Padget et al. revealed that hemodynamic force does not alter the ability of the
vSMCs to proliferate or differentiate and thus, there was no change in the total number of
vSMCs. Instead, vessels exposed to high-hemodynamic force (high-flow vessel) promote the
recruitment and attachment of unattached/migratory vSMCs from neighboring low-flow
capillaries. Thus, hemodynamic force is an upstream signal controlling the extent of vSMC
coverage and hence the tunica media formation. What remains unknown are the molecular
mechanisms governing how the unattached/migratory vSMCs recruit to the high-flow vessels
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and how they subsequently attach to the high-flow vessels instead of the low-flow vessels that
they encounter along their journey.

Hypothesis
Though we now know that hemodynamic force is required to regulate the extent of
vSMC coverage, we still do not know the molecular mechanisms governing the recruitment and
attachment of vSMCs to high-flow vessels. The premise of my thesis is to better understand the
molecular mechanisms specifically governing why migrating/unattached vSMCs attach to the
high-flow vessels, while avoiding attachment to low-flow vessels. I propose that to high
hemodynamic force on blood vessel regulates endothelial expression of several genes to control
vSMCs attachment. This concept is described in the following hypothesis.
If hemodynamic force modulates expression of extracellular matrix (ECM) and ECM
remodeling genes that promote deposition of a thick basement membrane around immature highflow vessels, then this will increase its adhesiveness to migrating vSMCs.
How (molecularly) does flow/force affects ECM expression or deposition? I posit that the
endothelium of high-flow vessel causes some change in protein expression that increases its
adhesiveness to vSMCs. There are several candidate genes that may be involved in promoting
ECM formation in high-flow vessels. This can occur in two ways: 1) hemodynamic force
regulates endothelial expression of ECM genes, or 2) hemodynamic force regulates endothelial
expression of genes that regulate ECM deposition. For example, in the first way, there are
several ECM proteins like collagen, laminin, fibronectin, perlecan, and nidogen. Hemodynamic
force may upregulate the expression of these ECM proteins resulting in a thicker ECM.
Considering that vSMCs express integrin proteins, which are transmembrane proteins that anchor
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cells to the ECM, then tissues that have a thicker ECM will more likely adhere to vSMCs
(Yousif, Russo, 2013). In the second way, ECM gene expression may not be altered, but
basement deposition could still be affected by modulating matrix metalloproteinase (MMP) and
tissue inhibitor of matrix metalloproteinase (TIMP) gene expression. During embryogenesis,
MMPs and TIMPs play a balancing act at promoting ECM degradation or preventing ECM
degradation by inhibiting MMP activity, respectively. Due to the opposing effects of MMPs and
TIMPs, I posit that high-flow blood vessels may downregulate MMPs and upregulate TIMPs
expression to promote formation of a thicker ECM (or basement membrane of the endothelium).
An opposite expression pattern might be found in low-flow vessels. If this occurs, this may
explain the difference in adhesiveness of vSMCs to different vessels of the hierarchy.
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MATERIALS AND METHODS

Mouse Husbandry
Mice were accommodated in the Missouri State University Temple Hall vivarium and
this project was approved by the Institutional Animal Care and Use Committee (Breeding
Protocols: #18-018.0 [November 2017], #2020-21 [October 2020]; Experimental Protocols: #18019.0 [November 2017], #2020-22 [October 2020] see appendix). The National Institute of
Health’s animal care and use guidelines were followed when caring for mice. Mice were kept in
either an Ancare standard mouse cage or a standard rat cage with either a maximum of 4 mice
per mouse cage or 10 mice per rat cage. The rat cage also provided more space for movement
and enrichment (mouse wheel), while other forms of enrichment were provided in the mouse
cages. Animals were housed in a mammal room that has consistent air flow, a temperature set
between 20-23℃, and a diurnal cycle of 12h light/12h dark. Purina Labdiet 5001 was used as a
maintenance diet and Purina Formulab diet 5008 was given when mice were used for breeding or
experimental purposes. A veterinarian would evaluate the health of the mice at a regular weekly
interval, while vivarium staff and Dr. Udan’s lab personnel would provide an additional
evaluation on a daily basis. Using the breeding protocol, mice were bred to expand the line. Mice
having the following mutation, myosin regulatory light chain 7 (Myl7+/-), and on a CD1
background were bred and a colony maintained to ensure sufficient availability of mice for the
study. Mice needed for this study were Myl7+/- females at an ideal age of 2-8 months, and Myl7+/males at an ideal age of 2 months to one year. To collect embryos for experiments, a
heterozygous Myl7+/- dam was bred with a heterozygous Myl7+/- stud. Plugs were checked daily
and every morning. Presence of a plug in the afternoon would mark the female having embryos
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that are at embryonic day (E) 0.5, and the pregnant female would then be humanely euthanized
10 days later to collect E10.5 mouse embryos for the project.

Embryo Collection and Genotyping
To collect embryos, pregnant dams were euthanized by CO2 inhalation followed by
cervical dislocation. Dissections were done to remove the uterus, and the uterus was moved to a
Petri dish full of ice-cold phosphate buffer saline (PBS). Embryos were dissected out of the
uterus, while keeping the yolk sac intact. At this point, the procedure would differ depending on
whether embryos were used for isolating RNA from the yolk sac tissue (for quantitative
polymerase chain reaction [qPCR] studies) or to prepare the embryos for cryosectioning and
immunostaining. For qPCR studies, yolk sacs were isolated per embryo for the purposes of
extracting RNA, while the corresponding embryos were used to determine the genotype of the
respective yolk sacs. For the cryosection/immunostaining experiments, embryos were prepared
for cryosectioning, while yolk sacs were used for genotype determination.
Genotyping was an important aspect of the study, as comparisons needed to be made
between the control group (Myl7+/- embryo) and the experimental group (Myl7-/- embryo). The
Myl7 gene is an atrial specific myosin that is required for contractility of the atria of the heart.
The null mutation does not result in a phenotype when heterozygous. However, homozygous
mutant embryos have impaired heart contractility and poor blood flow. Thus, mutant embryos
were used to determine the effect that poor blood flow has on the development of the embryonic
vasculature. To genotype the embryos or yolk sacs, DNA was extracted from the relevant tissue.
If extracting DNA from embryos, only a piece of the embryonic tail was required. If extracting
DNA from yolk sacs, then the whole yolk sac was used. Regardless of the tissue type, samples
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were placed in a microcentrifuge tube and treated overnight at 55C with 200µL embryo lysis
buffer (50mM Tris, [pH 8.0], 100mM EDTA, 0.5% SDS) with 8µL of Proteinase K. The next
morning, phenol:chloroform:isoamyl alcohol reagent was added to each sample in a 1:1 ratio.
Then, the microcentrifuge tubes were shaken up and down for 20-30 times until the solution
turned white. Then, the tubes were centrifuged at a maximum speed of 13.3g for 10 minutes.
Next, the aqueous phase of the tubes (top layer) was transferred in a clean microcentrifuge tube,
and this was followed by precipitation of DNA with 100% isopropanol. After gently discarding
the solution, the DNA pellet was washed with 70% ethanol and centrifuged 10 minutes at 13.3g.
The ethanol was removed carefully, and tubes were dried at room temperature. The pellet was
then suspended with 75-100µL of distilled water and kept at 4°C to use later.
The DNA was used to determine the genotype of each tissue by performing PCR. To
determine presence of the mutation, the following primers were used: Myl7 mutant forward
primer (5’-3’) ACAGGGAATCACA, Myl7 mutant reverse primer (5’-3’) CGAACCTGGTCGA.
To determine the presence of the wild type version of the Myl7 gene, the following primers were
used: Myl7 wild type forward primer (5’-3’) GGCACGATCACTC, Myl7 wild type reverse
primer (5’-3’) ATCCCTGTTCTGG. To prepare the sample for PCR, a 40 µL reaction mixture
was prepared per sample by mixing 25µL of the Pro-Taq DNA polymerase master mix (Denville
scientific Inc, CB-4065-4), with 4µL of the forward and reverse primers, 20µL of distilled water,
and 1µL of genomic DNA. The PCR reaction was performed on a TECHNE thermocycler at the
following conditions: 95°C for 5 minutes, followed by 35 cycles of 95°C for 30s, 56.5°C for 30s,
and 72°C for 1 minute. At the end of the cycle, there was a final extension at 72°C for 5 minutes.
Electrophoresis of the amplicon was done in a 2% agarose gel supplemented with 20µL of
ethidium bromide and run at 100V. The Azure Biosystems c300 transilluminator and digital
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imaging system was used to visualize the presence or absence of mutant and wild type bands in
the respective samples.

qPCR
Obtaining Samples to Extract RNA. Yolk sacs were used to extract RNA. Yolk sacs
are thin tissues that are only comprised of endoderm and mesoderm with substantial vascular
structures. So, gene expression changes in yolk sacs usually denotes gene expression changes in
the vasculature. Yolk sacs were collected by dissecting E10.5 mouse embryos. The dissection
method is described above in the embryo collection and genotyping section. Six mutant and six
wild type yolk sacs were used for RNA extraction. The respective tails of the embryos were used
to determine the genotype of the yolk sacs.
RNA Extraction. RNA was extracted from yolk sacs using Qiagen RNeasy mini kit (cat.
no. 74104) and following the company’s instructions. Briefly, 400µL of RLT buffer
supplemented with 4µL of β-mercaptoethanol (β-ME) was added to each yolk sac. Then, the
yolk sacs were disrupted by pipetting. After centrifuging the lysate for 3 minutes at maximum
speed, the supernatant was carefully transferred to a new microcentrifuge tube. Four hundreds
micro liter of 70% ethanol was added to the tube and the mixture was then transferred into a
RNeasy mini column which was placed into a 2 ml collection tube. This tube was then
centrifuged for 15 secs at maximum speed. After, the flow-through was discarded. Subsequently,
350µL of RW1 buffer was poured into the RNeasy mini-column, centrifuged for 15 secs, and the
flow-through was discarded after. The RNeasy mini column was then treated with a mixture of
RDD buffer and DNase for 15 mins. To eliminate DNA nucleotides remaining on the column,
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the column was subsequently washed first with the RW1 buffer then the RPF buffer using
similar procedures as described above.
To extract RNA from the column, the RNeasy column was then placed in a new 2 ml
collection tube and centrifuged for 1 min at maximum speed to dry the membrane. After drying,
the RNA column was transferred to a new 1.5mL collection tube and 40µL RNase free water
was pipetted directly onto the spin column. Finally, the tube was centrifuged for 1 min and the
spin column was disposed of. The flow-through that has been collected at this point contains
RNA, which was preserved at -80°C for further use.
Primer Design. Primer design involves multiple steps. At first, the sequence of the gene
of interest for the qPCR study was obtained by using the Ensembl website
(http://www.ensembl.org/index.html). The desired transcript was then selected and downloaded.
After opening the document in Microsoft word, the exon was marked in red font. To minimize
the amount of troubleshooting in the design of efficient primers (for PCR), the Thermo Fisher
Scientific qPCR website was used to find the genomic map of efficient primers used by the
company. Primers supplied by the Thermo Fisher company are verified for their efficiency, but
these primers are expensive, and the sequence information is proprietary. However, the company
does publish the approximate locations of these efficient primers (i.e., the exon-exon
boundaries), and the predicted size of the PCR product made using a cDNA template. Thus, the
sequence of these efficient primers can be deduced for each gene. Based on the exon-exon
boundaries of the genomic map provided by Thermo Fisher Scientific, primers were designed
from those exon sequences. Sequence information of these exon-exon boundary were used in the
Primer 3 program/website (https://bioinfo.ut.ee/primer3-0.4.0/) and the parameters were adjusted
to identify potential primers that span the intron and would produce a 50-125 bp amplicon from a
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cDNA template. A successful design of primers would reveal various options of forward and
reverse primers that would produce the correct amplicon. These primers were then validated
subsequently. Further, these primers were tested in an in-silico PCR (UCSC in silico PCR) to
ensure that they will not amplify other regions of the genome.
Primers were designed to detect different ECM and ECM-related genes. The forward and
reverse primer sequence of those genes are described in Table 1.

Table 1: Primers used in my study
Primer
Forward primer
Name
Collagen GAGAAGGCGCACAATCAAG
-IVa
MMP-9
TAATTGGGGCTGGCTTACAG

Reverse primer
TGGATGTTGCAGTAGGCAAA

Company
name
Invitrogen

TCACACGCCAGAAGAATTTG

Eurofins

Lama1

CTAAGAATGGCGTCCTCCTG

CACCGTTGTTGACGTGAAAT

Eurofins

Fn

ATTTGCTCCTGCACGTGTTT

CAGGTCTACGGCAGTTGTCA

Eurofins

HsPg2

GCCTCTGTCAAGATGGCTTC

AGGTGCCACCATTCAGACAT

Eurofins

Lama 4

TGTTTGTTGGAGGTGTTCCA

AATTACAAAGTGGCGGATGC

Eurofins

Lamac1

GAAAGGCCAAAAACCTGTCA

AGGGAGCCTTCGATCTCATT

Eurofins

Nidogen- ATTCTCGCACAGGACAACCT GTTCAGGCATTCTGCCCTAT
1
Nidogen- GGATGGCAGAGAGCTACAGG CCACAGATGGAGGAGTCACA
2

Eurofins

PPIA

CACAAACGGTTCCCAGTTTT

TTCACCTTCCCAAAGACCAC

Eurofins

MMP-2

ACCCAGATGTGGCCAACTAC

GGTTTCAGGGTCCAGGTCAG

Eurofins

TIMP -1

GCGTACTCTGAGCCCTGCT

TCTCCAGTTTGCAAGGGATAG Eurofins

TIMP-2

AGAAGAGCCTGAACCACAGG GTCCATCCAGAGGCACTCAT
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Eurofins

Eurofins

The next step was to check the primer validity by performing PCR and qPCR to
determine whether the primers amplify one single amplicon or different amplicons. In PCR,
primer validity was checked by using cDNA instead of genomic DNA. A master mix was
prepared using the previously described PCR protocol. Two control samples were used, one
without cDNA and another without primers to validate whether there are any mispriming events.
Each PCR tube contained a 40µL reaction volume, and for control samples, the volume was
adjusted with PCR grade water. The PCR was run following the parameters described above in
genotyping section.
In the qPCR, primer validity was checked by using wild type cDNA as a sample. The
master mix was prepared according to the qPCR protocol, and aliquoted to the appropriate well
of a 96-well plate. The qPCR was run following the parameters described below in the qPCR
section. The melt curves and CT values were used to determine which primers could be used for
the experiment.
cDNA Synthesis. For the qPCR experiments, a two-step system was used, and as such,
the cDNA was synthesized in the first step. The protocol for cDNA synthesis was followed from
Promega’s GoScript reverse transcriptase system (Promega: A5000). To synthesize cDNA, the
RNA concentration for each sample was measured using the Qubit RNA BR assay kit
(Invitrogen, REF: Q10210) and the Qubit 3.0 fluorometer (Company: Invitrogen, Catalog
Q33216). After determining the RNA concentration for each sample, the next phase of the
experiment (cDNA synthesis) took place using the Promega GoScript Reverse Transcriptase kit
and protocol (Promega: Cat #A60001). Briefly, to ensure that all samples result in a similar
cDNA concentration, the RNA concentrations of each cDNA synthesis reaction were adjusted to
the same concentration, and q.s. to a total volume of 8μL per PCR tube. To each RNA sample,
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1µL of random primer, and 1µL of oligo(dt) primer was added, yielding a final volume of 10μl
per tube (first reaction mix). PCR tubes were run in a thermal cycler at 70°C for 5 mins followed
by 4°C for 5 mins. For each sample, 10μL of the reverse transcription reaction mix (1.5µL of
nuclease free water, 4µL Go-Script 5X reaction buffer, 2.0µL MgCl2, 1µLPCR nucleotide mix,
0.5µL Recombinant RNasin Ribonulease inhibitor and 1µL GoScript Reverse Transcriptase) was
made and placed on ice. Upon completion, 10µL of the reaction mix was combined with 10µL of
the first reaction mix. This was then placed in a thermal cycler for another reaction at 25°C for 5
mins, 42°C for 1 hour, and 70°C for 15 mins. The mixture was aliquoted in a new
microcentrifuge tube and kept at -80°C for further use.
The cDNA concentration was measured in Qubit 3.0 fluorometer by using Qubit ssDNA
assay kit (Invitrogen by Thermo Fisher Scientific).
qPCR Procedure. The qPCR experiment was done to see the change of ECM
expression in high-flow versus low-flow vessels (i.e., yolk sac tissues). A qPCR plate was
designed using the Thermo Fisher Scientific software. Peptidylprolyl isomerase A (PPIA) which
catalyzes protein folding was used as housekeeping gene and to conduct this test, cDNA was
diluted according to the concentration of cDNA. Diluted cDNA was carefully added in the
appropriate well in the 96 well plate. Each cDNA sample had a reference standard which is
called technical replicate. The total 40 µL of qPCR master mix (GoTaq qPCR master mix, 2x
25µL, 13µL water, total primer 2µL) was prepared for each 10µL cDNA. The master mix was
combined with each 10µL cDNA template and centrifuged briefly to mix properly. The qPCR
reaction was performed using the QuantStudio 6 pro Real-time PCR system under the following
conditions: 1 cycle of polymerase activation at 95°C for 2 minutes, 40 cycles of denaturation at
95°C for 15 secs followed by 40 cycles of annealing/extension at 60°C for 1 minute, and the
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final step is 1 cycle of dissociation at 60°C. After completion of the test, qPCR data was
transferred to a personal Thermo Fisher account via a cloud-based system.

Data Analysis
Data analysis was done by using Microsoft Excel software. CT values were taken to
calculate gene expression change by using 2-∆∆Ct method (Pfaffl, 2001). Student’s t-test was used
to determine any gene expression change between reduced versus normal flow yolk sacs.

Cryo-sectioning
Embryos were processed in different steps to perform Cryosectioning. At first, tissues
were fixed 1 hour in 4% paraformaldehyde (PFA) at room temp (RT) followed by washing 4x10
mins each in PBS at 4 deg. The next step was dehydrating the embryos in 15% sucrose at 4°C
overnight (O/N), and then embedding the embryos in 30% sucrose at 4°C O/N. Then, embryos
were prepared for optical cutting temperature (OCT) penetration by submerging in 1:1 30%/OCT
for 6 hours, and again in 1:2 30% sucrose /OCT for 6 hours at 4°C. Finally, an OCT block was
prepared by embedding embryos in OCT on dry ice. Embryo sections (10µm) were prepared
from the OCT blocks using a cryostat (Leica CM1860 UV) set at -26°C and placed onto polylysine coated positively charged slides. Slides were dried at RT for 6 hours and preserved at 80°C to use for immunostaining later.

Immunostaining
For immunostaining, slides were post-fixed in 4% PFA for 10 mins at RT. Slides were
marked with PAP pen followed by washing 4 times for 10 mins each with PBT (phosphate
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buffered saline with 0.1% Triton X-100). Then, samples were blocked in a blocking solution for
1 hour at RT. The blocking solution was prepared with 2% of normal donkey serum (NDS) in
PBT. Samples were then incubated with primary antibody overnight at 4°C.
Slides were washed 4 times with PBT 10 mins each at RT. After washing, slides were
incubated in secondary antibody for 1 hour at RT followed by 4 times washing with PBT 10
mins each at RT. Excess PBT was wiped from around the specimen and samples were mounted
with flourmount (Sigma-Aldrich, f6182). A coverslip was added to each slide and stored at 4°C
for imaging later. Primary and secondary antibodies used in this procedure are listed in Table 2.

Table 2: Antibody’s used in this study.
Antibody
Dilution
Anti-vascular
1:200
endothelial growth
factor Receptor-2
(primary antibody),
made in goat

Company
SIGMA

Incubation period
24 hours

Collagen-4 antibody 1:500
(primary), made in
rabbit.

BIO RAD

24 hours

MMP-9 antibody
(primary)

1:500

BIO RAD

24 hours

Alexa flour 488
donkey anti-goat

1:500

Invitrogen

1 hour

Alexa 568 donkey
anti-rabbit

1:500

Invitrogen

1 hour

Imaging
Imaging of the immuonstained frozen sections was done on the Olympus IX81-ZDC
inverted confocal microscope and imaging data were collected using the Slidebook 6.0 program

26

as the computer interface. Images were taken using the Olympus 40xUPlanSApo objective,
20xLUCPlanFLN (NA 0.45) objective, and 10xUPlanSApo (NA 0.4). Images were collected
using Hamamatsu EM-CCD digital camera and a 3i laser at 488nm and 561nm. Green and red
fluorescence intensity was set to 100, averaging was set to 8 and the exposure time was 50ms.
Different regions of the samples were imaged to find out basement membrane deposition for
both Collagen-IVa and MMP-9.
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RESULTS
Hemodynamic Force Modulates the Expression of ECM Genes
In previous studies in the Dr. Udan’s lab, it was determined that hemodynamic force
regulates recruitment and attachment of vSMCs from neighboring low-flow vessels to the
dominant high-flow vessel present within the developing yolk sac. But what has remained
unknown is the molecular mechanism that supports the attachment of migratory/unattached
vSMCs specifically to the high-flow vessel, as opposed to the low-flow vessels that the vSMCs
encounter during their migration. To explain this phenomenon, one hypothesis was formulated:
hemodynamic force modulates the expression of ECM and ECM-modifying genes to form a
thick basement membrane (BM) that enhances the attachment of vSMCs in high-flow vessels.
Formation of a thick BM on the abluminal side of the vessel (the side of the endothelium tissue
that does not contact blood flow) may cause the vessel to be more adhesive to extramural cells
(cells that surround vessels). Hence, any high-flow vessels present in the developing yolk sac
would have a thick BM, whereas the low-flow vessels would have a thin BM. This would favor
the unattached migratory vSMCs to specifically attach to the high-flow vessels.
To determine whether hemodynamic force regulates the expression of ECM or ECMmodifying genes, I compared the gene expression of normal-flow yolk sacs (i.e., Myl7+/- yolk
sacs that contains mostly blood vessels having a diversity of blood flow—(low- and high-flow
vessels) with that of reduced-flow yolk sacs (i.e., Myl7-/- yolk sacs that contain mostly blood
vessels having very low to absent blood flow). Since the yolk sac is a simple tissue comprised of
a double sheet of tissues (endoderm and mesoderm) that houses an extensive vasculature, I
expect that gene expression analysis will allow us to detect any differences in vessels exposed to
normal blood flow versus those exposed to reduce blood flow. The ECM genes that I sought to
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evaluate were the following: Collagen-4, Laminin1 alpha, Fibronectin, Lama4, Lamac1, Hspg2,
Nidogen 1, Nidogen-2. The products of these genes are deposited in the ECM to form the
basement membrane in the abluminal side of the vessel. I also wanted to evaluate whether blood
flow affected expression of ECM-modifying genes. These genes are those whose protein
products physically modulate the ECM by either breaking the ECM down (matrix
metalloproteinases [MMPs]) or genes that inhibit the function of enzymes that degrade the
matrix (tissue inhibitors of MMPs known as TIMPs). Though MMPs and TIMPs are a rather
large family of genes, I sought to evaluate those that are known to be expressed specifically in
the endothelium: MMP-9, MMP-2, TIMP-1, and TIMP-2.
Assessment of ECM gene expression differences in reduced-flow yolk sacs by qPCR
revealed no difference in the expression of Fibronectin, Lama4, LamaC, Laminin 1 alpha,
Nidogen 1, and Nidogen 2 (Figure 1). However, to my surprise, there was an increase in the
expression of Collagen IVa. The upregulation was significant, resulting in a ~ 3.75X (which is a
very large amount of change that is not common for these altered flow studies). In addition to the
Collagen IVa result, there was also a slight increase in Hspg2. Both of these were unexpected
results, as I posited that decreased blood flow would result in blood vessels secreting a thinner
ECM. Gene expression changes are calculated by CT value. CT values are mentioned in Table 3.
To assess whether reduced-flow causes the vessels to deposit less ECM of the BM,
perhaps flow regulates the expression of ECM-modifying genes. This category of genes includes
Matrix metalloproteinases (MMPs) that enhance breakdown of the ECM, or TIMPs (Tissue
inhibitor of matrix metalloproteinases) that act to inactivate MMPs. From my analysis, I
determined that TIMP-1 is upregulated 1.5 fold in reduced-flow embryos, and there was a
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dramatic upregulation in one of the two endothelial MMPs—MMP-9 (Figure 2) Thus, in the
reduced-flow yolk sacs, MMP-9 was upregulated by 5.5X.

Table 3: CT values for ECM and ECM related genes in control and experimental samples in the
qPCR study.
Name of the Average CT
Average CT
Average CT values
Average CT values for
genes
value for
values for
for housekeeping
housekeeping gene
Mutant
Normal-flow
gene PPIA for
PPIA for Normal-flow
reduced-flow control
mutant samples
control samples
samples
samples
Fibronectin 22.10
22.13
17.49
17.56
Laminin

24.78

25.05

17.86

17.90

Collagen
IVa
MMP-9

32.56

34.41

17.76

17.69

27.22

29.90

17.28

17.50

MMP-2

26.79

26.53

17.16

18.04

Hspg2

27.08

27.59

17.98

17.83

Lama4

26.76

27.22

18.44

18.46

Lamac1

24.08

24.36

18.08

18.13

Nidogen 1

30.15

31.12

17.97

17.93

Nidogen-2

24.33

24.65

17.65

17.51

TIMP-1

25.41

25.84

18.38

18.26

TIMP-2

29.01

28.74

18.48

18.62
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Figure 1: Change in ECM mRNA expression in reduced-flow vessel. Collagen-IV is 3.75x
upregulated in reduced-flow yolk sacs. Hspg2 is upregulated 1.25x in reduce-flow vessel. There
is no significant change in other ECM genes expression due to low hemodynamic force.
Statistical significance was calculated using standard error. Standard error is built into the result.
Student’s t-test was used. P-value <0.05 and <0.01 respectively.
Immunostaining Results
Based on the qPCR results, it is unclear how this affects BM formation in the reducedflow vs normal-flow vessels of the yolk sac. Thus, the ideal way to make sense of these results is
to assess the deposition of these proteins in vivo. I decided to use immunostaining to visualize
Collagen IVa deposition (as well as MMP-9) around high-flow and low-flow vessels. For this
study, the yolk sac vessels were not evaluated because the large high-flow vessels are very
difficult to find amongst all other vessels of the yolk sac in a section, because it would remove
morphological hallmarks found in the flat mounted yolk sacs. Thus, I decided to assess ECM
deposition of the BM of the large dorsal aortae found within the embryo. I wanted to evaluate
whether the immunostaining could be successful, thus I tested them out on wild type samples.
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Figure 2: Change in ECM remodeling genes expression in reduced-flow vessel. Mmp-9 is 5.5x
upregulated in reduced-flow mutant vessel. There is no change in other ECM modifying genes
due to low hemodynamic force. Statistical significance was calculated using standard error.
Standard error is built into the result. Student’s t-test was used. P-value <0.05 and<.01
respectively.
Collagen IVa is diffusely distributed throughout the tissue; however, particularly around
the epithelial tissues (such as the endothelium of the dorsal aortae, as well as the epithelium of
the foregut) where the Collagen IVa staining was very abundant and seemed to be located in a
dense band where the BM is expected to be (Figure 3). My data provide evidence of Collagen
IVa staining. The Collagen IVa staining did seem to be expressed at low levels in other tissues,
which is to be expected for a widely expressed ECM gene. I did not use any primary antibody
control. Flk1 is a cell membrane receptor tyrosine kinase also designated as VEGFR-2.
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Figure 3: Dorsal Aorta cross section of normal-flow embryos were labeled with Flk1/AlexaFlour
488 and Collagen IVa antibody. Endothelium of dorsal aorta showing thick band of collagen in
basement membrane. Collagen-IVa is also expressed in other structures at low level.
MMP-9 is also distributed in a similar manner in the BM of the endothelium of the dorsal
aortae, and a little bit around the much smaller foregut. However, the staining appeared to be
more diffuse a little further from the endothelium (green staining), which is to be expected for a
secreted molecule (Figure 4). Also, MMP-9 seems to be expressed in other tissues, which is not
unexpected, because it is not an endothelial-specific gene.
Another major issue that is very common when analyzing vessel cross sections in
embryonic samples is the presence of blood cells, which are highly autofluorescent. Further, the
fixation process can increase this autofluorescence. So, within the blood vessels there can be
blood trapped inside, and that blood autofluorescence is present using both types of excitation
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Figure 4: Dorsal Aorta cross section tissue of normal-flow embryos were labeled with
Flk1/AlexaFlour488 and MMP-9 antibody. Mmp-9 staining is detected in the endothelium of
dorsal aorta and to a lesser amount in the foregut. Other structures also are expressing MMP-9 at
a low level.
lasers (488 nm and 561nm) resulting in enhanced red and green background staining inside the
dorsal aortae (unless vessel sections lack blood).
The critical experiment, however, was to compare these stainings with that of Myl7-/(reduced-flow embryos). But the mutant embryos we collected were decaying and we could not
get appropriate samples to observe Collagen-IVa and MMP-9 deposition in the BM of dorsal
aortae. Moreover, due to time restrains it was not possible to go for further embryo collection
and processing. However, based on the qPCR data, I anticipate that the dorsal aortae of these
embryos would exhibit high MMP-9 expression.
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With the Collagen IVa result, to support our hypothesis, I would expect to see that
Collagen IVa would be downregulated in reduced flow. However, the qPCR data shows the
opposite result. The ultimate goal would then be to determine whether this translates to protein
levels.
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DISCUSSION
The premise of this research study has been to determine the molecular mechanism
governing the attachment of unattached/migratory vSMCs to proximal blood vessels exposed to
high hemodynamic force/high blood flow. This process of blood vessel maturation is crucial to
ensure that proximal vessels receive the appropriate thickness/coverage of the tunica media layer
around blood vessels. A thicker coverage is not needed at the same degree in more distally
located vessels that are exposed to lower hemodynamic force/low blood flow. This study was
conducted to determine whether there are any changes in the gene expression pattern of ECM
and ECM-modifying genes between high-flow versus low-flow vessels that may explain the
formation of a thicker BM and more vSMCs attachment to high-flow vessels. The mechanism
for how vSMCs attach to ECM proteins could be explained by integrin-mediated adhesion.
Integrins are heterodimeric transmembrane proteins that promote vSMC-endothelial adhesion by
binding to ECM proteins of the basement membrane located in the abluminal side of the blood
vessel endothelium. Conditional knock-out studies showed that loss of integrin β1 prevents the
attachment of vSMCs to endothelial cells (Abraham, Kogata, Fässler, & Adams, 2008). Thus, it
seems that integrin-mediated adhesion is important for vSMC attachment. It was reported in
another study that integrin α5β3 is required for vSMC attachment to the endothelial BM.
Moreover, different ECM proteins like Collagen, Laminin, Fibronectin, Hspg2 can bind with
different subunits of integrin receptor (Scheppke, Murphy, et al., 2012). I thus proposed a
hypothesis that hemodynamic force may upregulate the expression of ECM genes or alter the
expression of ECM-modifying genes that normally act to control ECM deposition in the BM to
enhance the integrin- mediated vSMC adhesion to endothelial cells.
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The qPCR experiments conducted in this study, comparing reduced-flow yolk sacs with
normal-flow yolk sacs, revealed conflicting data. In support of the hypothesis, I observed an
upregulation of MMP-9 in reduced-flow yolk sacs, which may explain why low-flow vessels
have less deposition of ECM proteins in the BM. However, conflicting results revealed an
increase in Collagen IVa expression in reduced-flow yolk sacs, which does not fit with our
hypothesis.
MMPs are tissue remodeling genes known to be expressed in many cell types, including
in endothelial cells, and which act by degrading ECM proteins for different reasons such as to
remodel repairing tissue, to promote immunological cell migration through tissues, and to
promote changes in development. Thus, MMPs play an important role in modifying tissue
development such as with the changes that take place during vasculogenesis and angiogenesis
(Van Hinsbergh, Engelse, & Quax, 2006). I speculate that vessels exposed to reduced blood flow
may upregulate expression of specific MMPs that are known to be expressed in the endothelium
of blood vessels and downregulate expression of endothelially expressed TIMPs. By
upregulating MMPs, this may enhance breakdown of the BM, while downregulation of TIMPs
may enhance the function of MMPs. Interestingly, my results revealed that there was a 5.5 fold
upregulation of MMP-9 in the reduced-flow yolk sacs as compared to normal-flow yolk sacs.
Though there was no change in expression MMP-2, the upregulation in MMP-9 expression was
significant and congruent with the hypothesis. Thus, MMP-9 may act to breakdown the ECM
within low-flow vessels, much more so than in high-flow vessels that express a lower level of
MMP-9. This may support the model that the endothelium of high-flow vessels has a thicker
BM. But there was also a 1.5 fold upregulation of TIMP-1 which is unexpected result because
upregulation of TIMPs can downregulate MMP-9.
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However, findings from this study also showed that Collagen IVa exhibited a ~ 3.75 fold
upregulation in the reduced-flow yolk sacs. The observed upregulation is an unexpected result as
increased Collagen IVa production and deposition should lead to enhanced adhesiveness of
vSMCs to low-flow blood vessels. This result is opposite of the expectation. However, it is
possible that the basement membrane deposition is still diminished in the reduced-flow yolksacs, but by another means such as modulating expression of ECM modifying genes, and the
observed increased in Collagen IVa expression could be caused by a negative feedback loop.
Hspg2 is also showed 1.25 fold upregulation in reduced-flow vessels which is also unexpected
because upregulation of Hspg2 can help in thick BM formation, which is contrary to the
hypothesis.
Since it is not possible to make a conclusion from these results based on gene expression
changes alone, I then set off to perform immunostainings to qualitatively assess whether there is
change in protein expression for Collagen-IV and MMP-9 around the dorsal aortae vessels
between reduced-flow and normal-flow embryos. The benefit of immunostainings is that it not
only allows for observing changes in protein levels (which do not always match with changes in
RNA transcript levels), but it also provides resolution for determining where in the tissues any
changes in these proteins will be found (preferably around the endothelium). As previously
mentioned, due to time restrictions I was unable to assess Collagen IVa and MMP-9 protein
expression in reduced-flow embryos but did observe both Collagen IVa and MMP-9 staining
surrounding the endothelium in the region where the BM would be expected to be found. Upon
completion of these experiments the final expectation is to observe a thick BM (Collagen-IVa)
surrounding the dorsal aortae of normal-flow embryos, with a thinner BM around the dorsal
aortae of reduced-flow embryos. Even though this result counters that of the observed changes in
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Collagen-IVa mRNA levels, it is possible that hemodynamic force can modulate translational or
post-translational mechanisms of gene regulation to encourage Collagen-IVa protein production
(even upon diminished mRNA production). Regarding MMP-9 expression, I expect the opposite
expression pattern, which is supported by the gene expression studies.
Other ECM proteins like Laminin, Fibronectin, Nidogen, Hspg2 may deposit around the
dorsal aortae of the normal-flow embryos. Here, the mechanisms again could be translational or
post-translational mechanisms of gene regulation that are coopted by hemodynamic force.
Immunostainings also could be done with these ECM and ECM related proteins to see any
difference in the protein expression.
In another model, it is possible that integrin-B1 (known to be expressed in vSMCs) is
upregulated in vSMCs when they are in close proximity to high-flow vessels. It is likely that for
this occur, the vessels must be receiving an unidentified paracrine factor that is upregulated by
the endothelial cells of high-flow vessels. This paracrine factor might play a role to promote
integrin-B1 expression and increase adhesiveness of local vSMCs to vessels that have a BM
(even if the BM is not more thick). This could be tested by immunostaining.
Because MMP-9 resulted in the highest-level increase in expression, in reduced flow yolk
sacs, in future studies, it will be important to explore the role of this gene in vSMC attachment.
Thus, future experiments could be exposing cultured mouse embryos with an Mmp9 inhibitor
(such as an antagonist or a blocking antibody). Since MMP-9 would be expected to be expressed
at a high level in the distal, low-flow capillary region of the yolk sac, then MMP-9 inhibitors
may enhance attachment of the vSMCs to the distal capillaries, even in the normal-flow embryos
Though, this study will be regarded as basic science research, my findings could have
important therapeutic implications. Understanding the role of ECM and ECM modifying genes
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in BM formation could be used to manipulate vSMCs attachment to treat different vascular
diseases. For example, vascular aneurysms are characterized by weakening and ballooning of
vessel wall, partially caused by the depletion of tunica media that are susceptible to rupturing and
hemorrhaging. Currently, endovascular stents are used to treat abdominal aortic aneurysms,
however, many patients encounter recurrent aneurysm events, leading to a reduced life
expectancy (Avishay, 2021). As stents can be seeded with drug to render localized treatment
(García-García, Vaina, Tsuchida, & Serruys, 2006), stents could be seeded with ECM and ECM
remodeling factors to promote attachment of vSMCs to the thin vessel walls to prevent further
event. Moreover, knowledge gained from this study can be utilized in designing artificial
vasculature in tissue-engineering field. For example, if endothelial BM formation is the key to
enhance endothelial-vSMCs attachment, proximal vessel could be genetically modified by gene
editing to promote expression of ECM genes or downregulate expression of MMP genes. In
summary, my basic science research could pave the way of probable clinical advancement.
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APPENDIX: IACUC APPROVAL

April 18, 2022
RE: IACUC protocol 2020-21 and 2020-22
Hello Israt Jahan,
IACUC protocol #2020-21 entitled “Breeding protocol for the ‘blood vessel maturation and
heart morphogenesis’ project” and 2020-22 “Blood vessel maturation and heart
morphogenesis” were approved for 10/16/2020 to 10/15/2023 and you are an approved
member on the protocols.
Thank you and if you need anything in the future regarding this protocol, please contact me
either via email (Johnnapedersen@missouristate.edu) or at 417-836-3737.

Sincerely,
Johnna Pedersen
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